Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer

Trial Profile

Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ALRN 6924 (Primary) ; Cytarabine
  • Indications Acute myeloid leukaemia; CNS cancer; Hepatoblastoma; Lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Retinoblastoma; Rhabdoid tumour; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 03 Apr 2019 Enrollment began in October 2018. Up to 69 patients will be enrolled as per trial design presented at the 110th Annual Meeting of the American Association for Cancer Research.
    • 03 Apr 2019 Trial design presented at the 110th Annual Meeting of the American Association for Cancer Research
    • 01 Nov 2018 According to an Aileron Therapeutics media release, this trial is being conducted under and agreement between the company and the Dana-Farber/Boston Children's Cancer and Blood Disorders Center.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top